[go: up one dir, main page]

CN111527069A - 一类喹啉衍生物 - Google Patents

一类喹啉衍生物 Download PDF

Info

Publication number
CN111527069A
CN111527069A CN201880081555.XA CN201880081555A CN111527069A CN 111527069 A CN111527069 A CN 111527069A CN 201880081555 A CN201880081555 A CN 201880081555A CN 111527069 A CN111527069 A CN 111527069A
Authority
CN
China
Prior art keywords
cancer
alkynyl
compound
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880081555.XA
Other languages
English (en)
Other versions
CN111527069B (zh
Inventor
张磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huajian Future Chengdu Technology Co ltd
Original Assignee
Chengdu Huajian Future Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Huajian Future Technology Co ltd filed Critical Chengdu Huajian Future Technology Co ltd
Publication of CN111527069A publication Critical patent/CN111527069A/zh
Application granted granted Critical
Publication of CN111527069B publication Critical patent/CN111527069B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一类喹啉‑4‑基环己烷类化合物，其药学上可接受的盐、水合物、溶剂化物或立体异构体，及其制备方法以及该类化合物单独或与其他药物联合使用在治疗具有IDO介导的色氨酸代谢途径病理学特征的疾病

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880081555.XA 2017-12-18 2018-12-18 一类喹啉衍生物 Active CN111527069B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017113598638 2017-12-18
CN201711359863.8A CN109928916A (zh) 2017-12-18 2017-12-18 一类作为ido抑制剂的喹啉-4-基环己烷类化合物
PCT/CN2018/121868 WO2019120198A1 (zh) 2017-12-18 2018-12-18 一类喹啉衍生物

Publications (2)

Publication Number Publication Date
CN111527069A true CN111527069A (zh) 2020-08-11
CN111527069B CN111527069B (zh) 2023-08-08

Family

ID=66982078

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711359863.8A Pending CN109928916A (zh) 2017-12-18 2017-12-18 一类作为ido抑制剂的喹啉-4-基环己烷类化合物
CN201880081555.XA Active CN111527069B (zh) 2017-12-18 2018-12-18 一类喹啉衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201711359863.8A Pending CN109928916A (zh) 2017-12-18 2017-12-18 一类作为ido抑制剂的喹啉-4-基环己烷类化合物

Country Status (2)

Country Link
CN (2) CN109928916A (zh)
WO (1) WO2019120198A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017192811A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2017192813A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107427499A (zh) * 2014-11-05 2017-12-01 弗莱塞斯生物科学公司 免疫调节剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427499A (zh) * 2014-11-05 2017-12-01 弗莱塞斯生物科学公司 免疫调节剂
WO2017192811A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2017192813A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use

Also Published As

Publication number Publication date
WO2019120198A1 (zh) 2019-06-27
CN111527069B (zh) 2023-08-08
CN109928916A (zh) 2019-06-25

Similar Documents

Publication Publication Date Title
EP3686196B1 (en) Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor
JP2025520714A (ja) 複素環置換ピリミドピラン化合物及びその使用
BR112021015853A2 (pt) Compostos de tieno[3,2-b]piridin-7-amina para o tratamento de disautonomia familiar
EP2970155A1 (en) Inhibitors of indoleamine 2,3-dioxygenase (ido)
JP6526275B2 (ja) Ｓｈｉｐ１モジュレーターおよびそれに関連する方法
JP7237010B2 (ja) Ｈｄａｃ６選択的阻害剤およびその製造方法と使用
KR20190009377A (ko) 티오펜 화합물 및 이의 합성 방법과 이의 의약에서의 용도
US10793570B2 (en) Methods and reagents for radiolabeling
CN111527069B (zh) 一类喹啉衍生物
CN113121417A (zh) 一种新型哌啶衍生物及其药物用途
EP4651946A1 (en) Compositions useful for modulating splicing
CN117242061A (zh) 用于治疗艰难梭菌的二氮杂卓衍生物
JP6951418B2 (ja) 抗ｈｃｍｖウイルス化合物
CN115260195B (zh) Egfr降解剂
CN109928923A (zh) 一类作为ido抑制剂化合物
CN109928920A (zh) 环己烷类化合物
CN109928990A (zh) Ido抑制剂的喹啉-4-基环己烷类化合物
CN109928924A (zh) 一类作为ido抑制剂
CN109928918A (zh) 氟代ido抑制剂
CN109928922A (zh) 一类环己烷类化合物
CN109928919A (zh) 作为ido抑制剂的环己烷类化合物
CN109928921A (zh) Ido抑制剂
CN109928917A (zh) 一类ido抑制剂化合物
CN109665992A (zh) 一类作为ido抑制剂的喹啉-4-基环己烷类化合物
CN121064205A (zh) 一类溴结构域抑制活性的化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 611130 unit 4, building 1, No.18, North Bayi Road, Yongning Town, Wenjiang District, Chengdu City, Sichuan Province

Patentee after: Huajian Future (Chengdu) Technology Co.,Ltd.

Country or region after: China

Address before: 611130 unit 4, building 1, No.18, North Bayi Road, Yongning Town, Wenjiang District, Chengdu City, Sichuan Province

Patentee before: CHENGDU HUAJIAN FUTURE TECHNOLOGY Co.,Ltd.

Country or region before: China

CP03 Change of name, title or address